Arbutus Biopharma (ABUS) Misses Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Arbutus Biopharma (ABUS) Misses Q2 EPS by 7c

Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update

August 5, 2019 7:31 AM EDT

- Appointed William Collier, with decades of leadership experience in antivirals, President & CEO

- Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor in subjects with chronic hepatitis B

- Initiated dosing in healthy subject portion of Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent

- Received $20 million in gross proceeds from the sale of a portion of ONPATTRO royalty entitlement

Conference Call and Webcast Scheduled... More